Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -1.69% 2.90 2.80 3.00 2.95 2.90 2.95 364,032 09:39:53
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.7 -0.2 -0.1 - 2

Physiomics Share Discussion Threads

Showing 27151 to 27175 of 27175 messages
Chat Pages: 1087  1086  1085  1084  1083  1082  1081  1080  1079  1078  1077  1076  Older
DateSubjectAuthorDiscuss
21/1/2020
11:42
Private UK Unicorns in AI biotech Benevolent AI £1 Billion + ExScientia $1 Billion + Publicly listed UK AI biotech comps RENX £200m+ SENS £60m+ ETX £10m PYC £2m PYC and ETX are on any measure massively undervalued
the stigologist
21/1/2020
10:19
Whats occurring ?
1corsair
21/1/2020
09:27
Oh hello. Maybe people understanding read-across from SENS ?
the stigologist
20/1/2020
14:04
If you say so.
on target
18/1/2020
17:35
HEMO is so early stage it's not worth anything At the moment it's a liability. Will be burning a lot of cash to build any 'value'.
the stigologist
18/1/2020
14:18
Yes, real junior pharma's with novel IP in this area such as HEMO might be snapped up this year. That could be made even more interesting by the insiders' 65% holding - they're not going to let it go without a fight.
on target
18/1/2020
11:13
Looking to build up its pipeline of future products, Eli Lilly (NYSE:LLY) aims to announce a $1B-5B deal for each quarter of 2020. • The acquisitions will focus largely on earlier stage opportunities across key therapeutic areas including oncology, pain, immunology, and neurology, quote from the CFO ! Note the immunology and oncology area, as I mentioned the hottest area in the Healthcare. They are joining a growing group of majors with “ have cash, will spend “.
the stigologist
17/1/2020
17:44
Nice to hear from C4X Am sure PYC had similar experience if they attended htTps://twitter.com/C4XDiscovery/status/1218216663394521089?s=20
the stigologist
17/1/2020
13:47
Texa - Oldest trick in the book .....lol Not that anyone should make investment decisions based BB banter. I do my own DD and its held me in good stead
optastic
15/1/2020
19:21
Iamgreat1 aka @thelongergame aka ZM19 on LSE Aka jammydodger (stopped posting on 6th December set up iamgreat1 on 6th December and ZM19 on LSE 8th December Deramps under one name pumps on other names
texaschaser
15/1/2020
16:01
The rampers have it a good go They tried to inflict the pain of this dog onto newbies by claiming last time it went to 30pNo one is fooled here and old stig is impaled like a muthaphooker
iamgreat1
15/1/2020
13:20
davevt, if you are correct why would Zahid Ali buy 3.5% of the company. based on his MO. I reckon he knows a hell of a lot more than you in this space. Also strange why Merck keeps coming back if its something drug companies do already. As I said...you have no idea what you are talking about
pol123
14/1/2020
15:01
Maybe news on the way. JP Morgan Healthcare Conference going on in the US alongside Biotech Showcase Physiomics partners Merck are GOLD Sponsors and Keynote Speakers Could be lots of very interesting deals and talks going on on sidelines
the stigologist
14/1/2020
11:46
Are you joking??? 😂 Pyc only do dose and frequency prediction for working cancer drugs in patient trials. I'll write that in layman's terms for you. The estimate how much of a drug to give a patient and how frequently, in a drug trial.. ...for cancer drugs only. No other drugs, just cancer drugs.. ..something drug companies do themselves already, obviously! How many working cancer drugs are made each year by all the drug companies. You could probably count it on one hand and have fingers left over. And then how many of those companies want or even need to use pyc? Pyc model is not Bio tech. It doesn't design or improve drugs, or discover drugs. It simply works on data to provide a best guess of an amount, no different to a paint company having to use a system to work out how much of what to make a colour. Their tech is SO old, their patents have actually expired 2 years ago. Yes, that's how old it is.
davevt
13/1/2020
21:25
davevt, you have no idea what you are talking about
pol123
13/1/2020
18:00
They are not a competitor for pyc. Pyc is not a biotech company either. Pyc is old tech, limited application, hence why hardly any customers.
davevt
13/1/2020
17:41
PYC should follow ETX ETX : Two trading days since Thursday evening's Proactive Investors Forum presentation. Two big positive candles on decent volume. Very tightly held stock (by Industry savvy investors (Norwood and Mortazavi)) Their 'comparitor' Exscientia is private but valued at c.£1bn and signed a £200m deal with Bayer recently. Very hot area is AI/ML/Computational Biology
the stigologist
12/1/2020
08:34
htTps://twitter.com/iancassel/status/1215966314952642560?s=20
the stigologist
11/1/2020
14:10
PYC Government partner htTps://twitter.com/MedDiscCat/status/1215649884319244296?s=20
the stigologist
10/1/2020
10:02
big deals going on in UK biotech AI Bayer yesterday linking with Exscientia www.proactiveinvestors.co.uk/companies/news/910325/frontier-ips-exscientia-signs-200mln-collaboration-deal-with-bayer-910325.html exscientia is $1bn unicorn imagine that sort of deal for £2m PYC ! I know some top management at Big Pharma, they're looking to throw around some serious money
the stigologist
06/1/2020
07:24
Excitement over
spacedust
03/1/2020
11:10
And Stig is still plugging this mess lol
davevt
03/1/2020
10:21
ETX presenting at Proactive next week www.proactiveinvestors.co.uk/register/event_details/228
the stigologist
30/12/2019
20:53
Really think Ali Mortazavi (experienced Trader, Financier and Biotech CEO) is onto something when he says biotech valuations are ridiculous and even 'bad companies' massively undervalued htTps://twitter.com/AAMortazavi/status/1211560310965972994?s=20
the stigologist
30/12/2019
11:38
Annual Report page 11 Personalised Medicine The personalised medicine and digital health space continues to generate significant interest from both investors and healthcare systems. Many start-ups in this area focus on the use of genetic markers or the pattern-recognition capabilities of artificial intelligence applications however we believe that there is a significant opportunity in the analysis of existing clinical data to identify better ways to treat patient using existing drugs and procedures. In April 2019 we completed our second Innovate UK funded project in this field in which we developed a demonstration version of a tool to optimise dosing of docetaxel in castrate resistant, metastatic prostate cancer patients. The key outcomes of the project were presented in a poster at the prestigious American Association for Cancer Research Annual Meeting in March 2019. In parallel, working with the Oxford Academic Health Sciences Network, we were able to access some of the UK’s leading clinicians in this space which culminated in our being invited to present at an event jointly sponsored by the Royal Marsden Hospital NHS Trust, the Institute of Cancer Research and the National Institute for Health Research. The Company is now focused on finding an appropriate commercial partner to gain any required regulatory approvals and make the tool available in a clinical environment. The Company assesses on an ongoing basis the opportunity for further grant funding either to progress existing projects or start new ones where appropriate but in parallel, the Company is also in discussion with several companies that have an established presence in this field. htTps://www.physiomics.co.uk/wp-content/uploads/2019/10/Annual-Report-for-12-months-to-June-30-2019.pdf
the stigologist
Chat Pages: 1087  1086  1085  1084  1083  1082  1081  1080  1079  1078  1077  1076  Older
Your Recent History
LSE
PYC
Physiomics
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200122 22:32:20